Background
-Two years ago, we presented the short term 6 month results of metformin plus DPP-4 inhibitor combination therapy when we can't reach the target below 7% of HgA1c with metformin plus pioglitazone combination that is best in terms of relieving insulin resistance in early diabetes, -Switching the pioglitazone to the DPP-4 inhibitor that improves insulin secretory dysfunction can be the next useful step to attain glucose control goal. -DPP-4 inhibitors that increase insulin secretion by glucose dependent manner can also relieve insulin resistance because they improve first phase insulin secretion defect and prevent late hyperinsulinemia. -DPP-4 inhibitor is also better than pioglitazone in weight aspect.
Result
• Sulfonylurea was added in 6% (7/111) and pioglitazone was added again in 7% (7/111) for adequate glucose control.
• The dose of DPP-4 inhibitor was decreased in 6% ( 7/111) during the follow up period.
• Metformin plus first dose of DPP-4 inhibitor was maintained in 80% ( 89/111).
-The dose of metformin was increased in 41 % ( 40/89 ) and unchanged in 42% ( 41/89 ) and decreased in 7%.
-The mean dose of metformin to maintain HgA1c target was elevated by 260 mg in the end.
-HgA1c was improved in 76% ( 68/89 ) from 7.40% to 6.66% and the metformin dose was increased by 240 mg. HgA1c was aggravated in 22% ( 20/89 ) from 6.85% to 7.22%. -HOMA-IR was improved in 46% ( 0.91±0.92 ) and aggravated in 53% (-1.25±1.17).
Mean HOMA-IR change was -0.24±1.51. -Mean weight was reduced by 2.23kg (±3.17) as a whole.
The weight was decreased in 72% (3.63±2.51) and increased in 19% (1.77±1.73).
Method
-Total 111 patients were followed by 26.5 month ( ± 9.7 ) after switching from metformin plus pioglitazone.
-15mg of pioglitazone that is usual dosage in this country was switched to DPP-4 inhibitors without changing the dose of metformin. -The change of medication during follow up was examined. -HgA1c level, insulin resistance index HOMA-IR, weight change before and after switching was compared in patients who maintained metformin plus first dose of DPP-4 inhibitor.
Conclusion
Although the dose of metformin was slightly increased to maintain glucose control target with time, metformin plus DPP-4 inhibitor combination can be a good treatment option in controlling blood glucose & maintaining insulin resistance & weight control as compared to metformin plus pioglitazone combination.
